To ask the Secretary of State for Health and Social Care, what plans his Department has to make it easier for secondary breast cancer patients to make use of compassionate access schemes.
Where an unmet need has been identified, the Early Access to Medicines Scheme (EAMS) run by the Medicines and Healthcare products Regulatory Agency provides opportunity for supply of medicines awaiting a licence. These are to be prescribed under the responsibility of the treating physician.
Atezolizumab in combination with nab-paclitaxel for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer was available to patients through EAMS from March to August this 2019. 57 patients were able to access treatment in England through this EAMS.